

## Oropharynx (HPV-Associated)

### **Cancers Staged Using This Staging System**

*Human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is staged using this system.*

### **Cancers NOT Staged Using This Staging System**

<i>These histopathologic types of cancer...</i>	<i>Are staged according to the classification for...</i>
<i>HPV-independent carcinomas of the oropharynx</i>	<i>Oropharynx (HPV-independent) and hypopharynx</i>
<i>Neuroendocrine carcinomas of the oropharynx</i>	<i>Oropharynx (HPV-independent) and hypopharynx</i>
<i>Mucosal melanomas</i>	<i>Mucosal melanoma of the head and neck</i>
<i>Salivary gland carcinomas</i>	<i>Salivary glands</i>

### **Identification of Primary Site**

<i>C01.9 Base of tongue, NOS</i>	<i>C10.0 Vallecula</i>
<i>C02.4 Lingual tonsil</i>	<i>C10.1 Anterior surface of epiglottis</i>
<i>C05.1 Soft palate, NOS</i>	<i>C10.2 Lateral wall of oropharynx</i>
<i>C05.2 Uvula</i>	<i>C10.3 Posterior pharyngeal wall</i>
<i>C09.0 Tonsillar fossa</i>	<i>C10.8 Overlapping lesion of oropharynx</i>
<i>C09.1 Tonsillar pillar</i>	<i>C10.9 Oropharynx, NOS</i>
<i>C09.8 Overlapping lesion of tonsil</i>	
<i>C09.9 Tonsil, NOS</i>	

### **Histopathologic Type**

<b>Code</b>	<b>Description</b>
8085	Squamous cell carcinoma, HPV-associated
8072	Non-keratinizing squamous cell carcinoma
8071	Keratinizing squamous cell carcinoma
8052	Papillary squamous cell carcinoma
8560	Adenosquamous carcinoma
8560	Ciliated adenosquamous carcinoma
8082	Lymphoepithelial carcinoma
8074	Spindle cell/sarcomatoid squamous cell carcinoma
8083	Basaloid squamous cell carcinoma

Sources: WHO Classification of Tumours Editorial Board. *Head and neck tumours*. Lyon (France): International Agency for Research on Cancer, 2023. (WHO Classification of Tumours series, 5<sup>th</sup>ed.; vol. 9).

International Agency for Research on Cancer, World Health Organization. International Classification of Diseases for Oncology. ICD-O-3.2 Online. Used with permission.

**Definition of Primary Tumor (T)**

T Category	T Criteria
<b>T0</b>	No evidence of primary tumor
<b>T1</b>	Tumor $\leq$ 2 cm in greatest dimension
<b>T2</b>	Tumor $>$ 2 cm but $\leq$ 4 cm in greatest dimension
<b>T3</b>	Tumor $>$ 4 cm in greatest dimension or extension to lingual surface of epiglottis
<b>T4</b>	Tumor invades any of the following: <ul style="list-style-type: none"> <li>• Larynx*</li> <li>• Deep/extrinsic muscle of the tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus)</li> <li>• Pterygoid muscles (medial and/or lateral)</li> <li>• Hard palate</li> <li>• Mandible</li> <li>• Pterygoid plates (medial and/or lateral)</li> <li>• Nasopharynx</li> <li>• Skull base</li> <li>• Encases carotid artery</li> </ul>

\*Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx.

**Primary Tumor Suffix**

(m) Multiple synchronous primary tumors

**Definition of Regional Lymph Nodes (N) Clinical N (cN)**

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No tumor involvement of regional lymph node(s)
<b>N1</b>	Tumor involvement of ipsilateral (同側) lymph node(s), all $\leq$ 6 cm in greatest dimension, <b>without</b> unequivocal imaging-detected and/or clinical extranodal extension
<b>N2</b>	Tumor involvement of ipsilateral lymph node(s), all $\leq$ 6 cm in greatest dimension, <b>with</b> unequivocal imaging-detected and/or clinical extranodal extension OR Tumor involvement of contralateral (對側) or bilateral (雙側) lymph node(s), all $\leq$ 6 cm in greatest dimension <b>without</b> unequivocal imaging-detected and/or clinical extranodal extension
<b>N3</b>	Tumor involvement of lymph node(s) $>$ 6 cm in greatest dimension OR Tumor involvement of contralateral or bilateral lymph node(s) <b>with</b> unequivocal imaging-detected and/or clinical extranodal extension

**Definition of Regional Lymph Nodes (N) Pathological N (pN)**

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No tumor involvement of regional lymph node(s)
<b>N1</b>	Tumor involvement of 1-4 lymph nodes <b>without</b> definitive pathological extranodal extension
<b>N1a</b>	Tumor involvement of 1 lymph node <b>without</b> definitive pathological extranodal extension
<b>N1b</b>	Tumor involvement of 2-4 lymph nodes <b>without</b> definitive pathological extranodal extension
<b>N2</b>	Tumor involvement of 1-4 lymph nodes <b>with</b> definitive pathological extranodal extension OR Tumor involvement of > 4 lymph nodes <b>without</b> definitive pathological extranodal extension
<b>N3</b>	Tumor involvement of > 4 lymph nodes <b>with</b> definitive pathological extranodal extension

**Regional Lymph Nodes Suffix**

(sn) Sentinel node procedure  
(f) FNA or core needle biopsy

**Definition of Distant Metastasis (M)**

M Category	M Criteria
<b>cM0</b>	No distant metastasis
<b>cM1</b>	Distant metastasis
<b>pM1</b>	Microscopic confirmation of distant metastasis

## AJCC Prognostic Stage Groups

## Clinical Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
T0	N1	M0	I
T1-T2	N0-N1	M0	I
T0-T2	N2	M0	II
T3	N0-N2	M0	II
T0-T3	N3	M0	III
T4	Any N	M0	III
Any T	Any N	M1	IV

## Pathological Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
T0	N1	M0	I
T1-T2	N0-N1	M0	I
T0-T2	N2-N3	M0	II
T3	N0-N2	M0	II
T3	N3	M0	III
T4	Any N	M0	III
Any T	Any N	M1	IV

Clinical Stage Group				
	N0	N1	N2	N3
T0	-	I	II	III
T1	I	I	II	III
T2	I	I	II	III
T3	II	II	II	III
T4	III	III	III	III
M1	IV	IV	IV	IV

Pathological Stage Group				
	N0	N1	N2	N3
T0	-	I	II	II
T1	I	I	II	II
T2	I	I	II	II
T3	II	II	II	III
T4	III	III	III	III
M1	IV	IV	IV	IV

## References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>

[https://www.amazon.com/gp/product/B0G2TCQQBM?ref\\_=dbs\\_m\\_mng\\_rwt\\_calw\\_tkin\\_16&storeType=ebooks&qid=1763560154&sr=8-13](https://www.amazon.com/gp/product/B0G2TCQQBM?ref_=dbs_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13)

## Salivary Glands

### Cancers Staged Using This Staging System

*All malignancies arising in the major and minor salivary glands are staged using this system.*

### Cancers NOT Staged Using This Staging System

<i>These histopathologic types of cancer...</i>	<i>Are staged according to the classification for...</i>
<i>Cutaneous squamous cell carcinomas</i>	<i>Cutaneous carcinoma of the head and neck</i>
<i>Mucosal squamous cell carcinomas</i>	<i>Specific head and neck primary site</i>
<i>Neuroendocrine carcinomas</i>	<i>Specific head and neck primary site</i>
<i>Lymphomas</i>	<i>Hodgkin and non-Hodgkin lymphoma</i>
<i>Sarcomas</i>	<i>Soft tissue sarcoma of the head and neck</i>
<i>Mucosal melanomas</i>	<i>Mucosal melanoma of the head and neck</i>

### Identification of Primary Site

#### Major Salivary Glands

*C07.9 Parotid gland* *C08.8 Overlapping lesion of major salivary glands*

*C08.0 Submandibular gland* *C08.9 Major salivary gland, NOS*

*C08.1 Sublingual gland*

#### Minor Salivary Glands

*C00.3 Mucosa of upper lip* *C12 Pyriform sinus*

*C00.4 Mucosa of lower lip* *C13 Hypopharynx*

*C00.5 Mucosa of lip, NOS* *C14 Other and ill-defined sites in lip, oral cavity*

*C01 Base of tongue* *and pharynx*

*C02 Other and unspecified parts of tongue* *C15.0 Cervical esophagus*

*C03 Gum*

*C04 Floor of mouth* *C15.3 Upper third of esophagus*

*C05 Palate*

*C30 Nasal cavity and middle ear*

*C06 Other and unspecified parts of mouth* *C31 Accessory sinuses*

*C09 Tonsil*

*C32 Larynx*

*C10 Oropharynx*

*C33 Trachea*

*C11 Nasopharynx* *C41.1 Mandible*

**Histopathologic Type**

<b>Code</b>	<b>Description</b>
8010	Carcinoma, NOS
8082	Lymphoepithelial carcinoma
8140	Adenocarcinoma, NOS
8147	Basal cell adenocarcinoma
8200	Adenoid cystic carcinoma
8310	Hyalinizing clear cell carcinoma
8407	Sclerosing microcystic adenocarcinoma
8410	Sebaceous carcinoma
8430	Mucoepidermoid carcinoma
8480	Mucinous adenocarcinoma
8500	Salivary duct carcinoma
8500	Intraductal carcinoma
8502	Secretory carcinoma
8502	Microsecretory adenocarcinoma
8525	Polymorphous adenocarcinoma
8550	Acinic cell carcinoma
8562	Epithelial-myoepithelial carcinoma
8980	Carcinosarcoma
8982	Myoepithelial carcinoma
8000*	<i>Neoplasm. malignant</i>

\* Histology is not ideal for clinical use in patient care, as it describes an unspecified or outdated diagnosis. Data collectors may use this code only if there is not enough information in the medical record to document a more specific diagnosis.

Sources: WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer, 2023. (WHO classification of tumours series, 5<sup>th</sup> ed.; vol. 9).

**Definition of Primary Tumor (T)**

T Category	T Criteria
<b>TX</b>	Primary tumor cannot be assessed
<b>T0</b>	No evidence of primary tumor
<b>Tis</b>	Carcinoma <i>in situ</i>
<b>T1</b>	Tumor $\leq$ 2 cm in greatest dimension without extraparenchymal extension*
<b>T2</b>	Tumor $>$ 2 cm but $\leq$ 4 cm in greatest dimension without extraparenchymal extension*
<b>T3</b>	<ul style="list-style-type: none"> <li>• Tumor <math>&gt;</math> 4 cm in greatest dimension and/or</li> <li>• Gross extraparenchymal extension (for major salivary glands)*</li> </ul>
<b>T4</b>	Tumor invades immediately and/or beyond adjacent structures
<b>T4a</b>	Tumor invades any immediately adjacent structures including: <ul style="list-style-type: none"> <li>• Skin</li> <li>• Bone**</li> <li>• Cartilage</li> <li>• Solid organ parenchyma</li> <li>• Esophagus</li> <li>• Trachea</li> <li>• Named nerve</li> </ul>
<b>T4b</b>	Tumor invades beyond any adjacent structures including: <ul style="list-style-type: none"> <li>• Encasement of carotid artery</li> <li>• Base of skull invasion (except nasopharynx)</li> <li>• Spinal column invasion</li> <li>• Intracranial invasion</li> <li>• Orbital apex</li> <li>• Prevertebral space</li> <li>• Mediastinal structures</li> <li>• Masticator space</li> </ul>

\*Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve, except those listed under T4a and T4b. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.

\*\*The following scenarios are not considered T category defining "bone invasion":

- 1) Destruction of intrinsic sinus bone in sinonasal primaries; 2) Erosion of cortical bone; 3) Primary intraosseous (central) salivary gland tumors.

**Primary Tumor Suffix**

(m) Multiple synchronous primary tumors

**Definition of Regional Lymph Nodes (N) Clinical N (cN)**

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No tumor involvement of regional lymph node(s)
<b>N1</b>	Tumor involvement of 1-3 lymph node(s), <b>without</b> unequivocal imaging-detected and/or clinical extranodal extension
<b>N2</b>	Tumor involvement of > 3 lymph nodes OR Tumor involvement of any lymph node(s), <b>with</b> unequivocal imaging-detected and/or clinical extranodal extension

**Definition of Regional Lymph Nodes (N) Pathological N (pN)**

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No tumor involvement of regional lymph node(s)
<b>N1</b>	Tumor involvement of 1-3 lymph node(s), <b>without</b> definitive pathological extranodal extension
<b>N2</b>	Tumor involvement of > 3 lymph nodes OR Tumor involvement of any lymph node(s), <b>with</b> definitive pathological extranodal extension

**Regional Lymph Nodes Suffix**

(sn) Sentinel node procedure  
(f) FNA or core needle biopsy

**Definition of Distant Metastasis (M)**

M Category	M Criteria
<b>cM0</b>	No distant metastasis
<b>cM1</b>	Distant metastasis
<b>pM1</b>	Microscopic confirmation of distant metastasis

**AJCC Prognostic Stage Groups**

When T is...	And N is...	And M is...	Then the stage group is...
Tis	N0	M0	<b>0</b>
T1	N0	M0	<b>I</b>
T2	N0	M0	<b>II</b>
T1-T2	N1	M0	<b>IIIA</b>
T3-T4	N0	M0	<b>IIIA</b>
T1-T2	N2	M0	<b>IIIB</b>
T3-T4	N1-N2	M0	<b>IIIB</b>
Any T	Any N	M1	<b>IV</b>

AJCC Stage Group			
	<b>N0</b>	<b>N1</b>	<b>N2</b>
<b>Tis</b>	<b>0</b>	-	-
<b>T1</b>	<b>I</b>	<b>IIIA</b>	<b>IIIB</b>
<b>T2</b>	<b>II</b>	<b>IIIA</b>	<b>IIIB</b>
<b>T3</b>	<b>IIIA</b>	<b>IIIB</b>	<b>IIIB</b>
<b>T4</b>	<b>IIIA</b>	<b>IIIB</b>	<b>IIIB</b>
<b>M1</b>	<b>IV</b>	<b>IV</b>	<b>IV</b>

## References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>  
[https://www.amazon.com/gp/product/B0G2TCQQBM?ref\\_=dbs\\_m\\_mng\\_rwt\\_calw\\_tkin\\_16&storeType=ebooks&qid=1763560154&sr=8-13](https://www.amazon.com/gp/product/B0G2TCQQBM?ref_=dbs_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13)

# Oropharynx (HPV-Associated)

## *Summary of Changes :*

- Changed from HPV-Mediated (p16+) Oropharyngeal Cancer to Oropharynx (HPV-Associated)
- Pharyngeal tonsil (adenoid) and tubal tonsils have been moved to the nasopharynx staging system
- Anterior surface of epiglottis has been included in this staging system and removed from the larynx staging system
- Addition of unequivocal imaging-detected extranodal extension (iENE) and/or clinical extranodal extension as a cN criterion: **iENE or clinical ENE increases N1 and N2 by one category**
- Addition of definitive pathologic extranodal extension (pENE) as a pN criterion:  
**pENE increases N1 and N2 by one category**
- Pathological N1 without definitive pENE is subdivided into  
**N1a (single node without definitive pENE) and N1b (2-4 nodes without definitive pENE)**
- Pathological stage II is revised to include T0-T2 N2-N3 M0 or T3 N0-N2 M0
- Pathological stage III is revised to include T3 N3 M0 or T4 Any N M0

## **Definition of primary Tumor (T) (紅字增修處)**

T Category	T Criteria
<b>T0</b>	No <b>evidence of primary tumor identified</b>
<b>T1</b>	Tumor $\leq$ 2 cm <b>or smaller</b> in greatest dimension
<b>T2</b>	Tumor $>$ <b>larger than</b> 2 cm but <b>not larger than</b> $\leq$ 4 cm in greatest dimension
<b>T3</b>	Tumor $>$ <b>larger than</b> 4 cm in greatest dimension or extension to lingual surface of epiglottis
<b>T4</b>	<p>Tumor invades any of the following :</p> <ul style="list-style-type: none"><li><b>Larynx*</b></li><li><b>Deep/extrinsic muscle of the tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus)</b></li><li><b>Pterygoid muscles (medial and/or lateral)</b></li><li><b>Hard palate</b></li><li><b>Mandible</b></li><li><b>Pterygoid plates (medial and/or lateral)</b></li><li><b>Nasopharynx</b></li><li><b>Skull base</b></li><li><b>Encases carotid artery</b></li></ul> <p><b>Moderately advanced local disease</b></p> <p><b>Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond*</b></p>

\*Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx.

### Definition of Regional Lymph Node (N) Clinical N (cN) (紅字增修處)

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No <b>tumor involvement of regional lymph node(s) metastasis</b>
<b>N1</b>	Tumor involvement of ipsilateral lymph node(s), all $\leq 6$ cm in greatest dimension, <b>without</b> unequivocal imaging-detected and/or clinical extranodal extension <del>One or more ipsilateral lymph nodes, none larger than 6 cm</del>
<b>N2</b>	Tumor involvement of ipsilateral lymph node(s), all $\leq 6$ cm in greatest dimension, <b>with</b> unequivocal imaging-detected and/or clinical extranodal extension OR Tumor involvement of contralateral or bilateral lymph node(s), all $\leq 6$ cm in greatest dimension <b>without</b> unequivocal imaging-detected and/or clinical extranodal extension <del>Contralateral or bilateral lymph nodes, none larger than 6 cm</del>
<b>N3</b>	Tumor involvement of lymph node(s) $> 6$ cm in greatest dimension OR Tumor involvement of contralateral or bilateral lymph node(s) <b>with</b> unequivocal imaging-detected and/or clinical extranodal extension <del>Lymph node(s) larger than 6 cm</del>

### Definition of Regional Lymph Node (N) Pathological N (pN) (紅字增修處)

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>pN0</b>	No <b>tumor involvement of regional lymph node(s) metastasis</b>
<b>pN1</b>	Tumor involvement of 1-4 lymph nodes <b>without</b> definitive pathological extranodal extension <del>Metastasis in 4 or fewer lymph nodes</del>
<b>N1a</b>	Tumor involvement of 1 lymph node <b>without</b> definitive pathological extranodal extension
<b>N1b</b>	Tumor involvement of 2-4 lymph nodes <b>without</b> definitive pathological extranodal extension
<b>pN2</b>	Tumor involvement of 1-4 lymph nodes <b>with</b> definitive pathological extranodal extension OR Tumor involvement of $> 4$ lymph nodes <b>without</b> definitive pathological extranodal extension <del>Metastasis in more than 4 lymph nodes</del>
<b>N3</b>	Tumor involvement of $> 4$ lymph nodes <b>with</b> definitive pathological extranodal extension

### Definition of Distant Metastasis (M) (紅字增修處)

M Category	M Criteria
<b>cM0</b>	No distant metastasis
<b>cM1</b>	Distant metastasis
<b>pM1</b>	Microscopic confirmation of distant metastasis

### AJCC Prognostic Stage Groups (紅字增修處)

#### Clinical Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
<b>T0</b>	<b>N1</b>	<b>M0</b>	<b>I</b>
<b>T0, T1-T2</b>	N0-N1	M0	I
T0-T2	N2	M0	II
T3	N0-N2	M0	II
T0-T3 <b>T4</b>	N3	M0	III
T4	<b>Any N</b> <b>N0, N1, N2 or N3</b>	M0	III
Any T	Any N	M1	IV

#### Pathological Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
<b>T0</b>	<b>N1</b>	<b>M0</b>	<b>I</b>
<b>T0, T1-T2</b>	N0-N1	M0	I
T0-T2	<b>N2-N3</b>	M0	II
<b>T3 or T4</b>	<b>N0-N2 N4</b>	M0	II
<b>T3 or T4</b>	<b>N3 N2</b>	M0	III
<b>T4</b>	<b>Any N</b>	<b>M0</b>	<b>III</b>
Any T	Any N	M1	IV

#### References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>  
[https://www.amazon.com/gp/product/B0G2TCQQBM?ref\\_=dbs\\_m\\_mng\\_rwt\\_calw\\_tkin\\_16&storeType=ebooks&qid=1763560154&sr=8-13](https://www.amazon.com/gp/product/B0G2TCQQBM?ref_=dbs_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13)

# Salivary Glands

## *Summary of Changes :*

- Changed from Major Salivary Glands to Salivary Glands as the staging system now includes minor salivary glands
- Includes **major and minor salivary glands**
- Removal of squamous cell carcinoma (SCC), neuroendocrine, basosquamous cell since they are not typical salivary gland origin
- Almost all SCCs in salivary gland are metastatic nodes from a skin primary or rarely from a mucosal primary
- Consolidation of major and minor salivary gland T category definitions  
Clarification of the definition of:
  - Extraparenchymal extension for T3
  - Bone invasion for T4
- Replacement of laterality with clinical lymph node number (1-3 vs > 3)
- Elimination of the cN3 category
- Addition of imaging-detected extranodal extension (iENE) in addition to clinical ENE as a cN criteria:
  - N1: 1-3 lymph nodes involved, **without** unequivocal iENE and/or clinical ENE
  - N2: > 3 lymph nodes involved, or any lymph node **with** unequivocal iENE and/or clinical ENE
- Replacement of laterality with pathological lymph node number (1-3 vs > 3)
- Elimination of the pN3 category
- Simplification of pN-positive categories:
  - N1: 1-3 lymph nodes involved **without** definitive pENE
  - N2: > 3 lymph nodes involved, or any lymph node **with** definitive pENE
- Confinement of M0 disease in Stages I, II, IIIA and IIIB, while reserving stage IV for M1 disease
  - Stage I: T1 N0
  - Stage II: T2 N0
  - Stage IIIA: T1-T2 N1 or T3-T4 N0
  - Stage IIIB: T1-T2 N2 or T3-T4 N1-N2

### Definition of primary Tumor (T) (紅字增修處)

T Category	T Criteria
<b>TX</b>	Primary tumor cannot be assessed
<b>T0</b>	No evidence of primary tumor
<b>Tis</b>	Carcinoma <i>in situ</i>
<b>T1</b>	Tumor $\leq$ 2 cm <del>or smaller</del> in greatest dimension without extraparenchymal extension*
<b>T2</b>	Tumor $>$ <del>larger than</del> 2 cm but $\leq$ <del>not larger than</del> 4 cm in greatest dimension without extraparenchymal extension*
<b>T3</b>	<ul style="list-style-type: none"> <li>Tumor <math>&gt;</math> <del>larger than</del> 4 cm <del>in greatest dimension and/or tumor having</del> extraparenchymal extension*</li> <li><b>Gross extraparenchymal extension (for major salivary glands)*</b></li> </ul>
<b>T4</b>	<p>Tumor invades immediately and/or beyond adjacent structures</p> <p><del>Moderately advanced or very advanced disease</del></p>
<b>T4a</b>	<p>Tumor invades any immediately adjacent structures including:</p> <ul style="list-style-type: none"> <li>Skin</li> <li><b>Bone**</b></li> <li>Cartilage</li> <li>Solid organ parenchyma</li> <li>Esophagus</li> <li>Trachea</li> <li>Named nerve</li> </ul> <p><del>Moderately advanced disease</del></p> <p><del>Tumor invades skin, mandible, ear canal, and/or facial nerve</del></p>
<b>T4b</b>	<p>Tumor invades beyond any adjacent structures including:</p> <ul style="list-style-type: none"> <li>Encasement of carotid artery</li> <li>Base of skull invasion (except nasopharynx)</li> <li>Spinal column invasion</li> <li>Intracranial invasion</li> <li>Orbital apex</li> <li>Prevertebral space</li> <li>Mediastinal structures</li> <li>Masticator space</li> </ul> <p><del>Very advanced disease</del></p> <p><del>Tumor invades skull base and/or pterygoid plates and/or encases carotid artery</del></p>

\*Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve, except those listed under T4a and T4b. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.

\*\*The following scenarios are not considered T category defining "bone invasion":

1) Destruction of intrinsic sinus bone in sinonal primaries; 2) Erosion of cortical bone; 3) Primary intraosseous (central) salivary gland tumors.

### Definition of Regional Lymph Node (N) Clinical N (cN) (紅字增修處)

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No <b>tumor involvement of regional lymph node(s) metastasis</b>
<b>N1</b>	<p><b>Tumor involvement of 1-3 lymph node(s), without unequivocal imaging-detected and/or clinical extranodal extension</b></p> <p><del>Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)</del></p>
<b>N2</b>	<p><b>Tumor involvement of &gt; 3 lymph nodes</b></p> <p><b>OR</b></p> <p><b>Tumor involvement of any lymph node(s), with unequivocal imaging-detected and/or clinical extranodal extension</b></p> <p><del>Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-);</del></p> <p><del>or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-);</del></p> <p><del>or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)</del></p>
<b>N2a</b>	<del>Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)</del>
<b>N2b</b>	<del>Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)</del>
<b>N2e</b>	<del>Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)</del>
<b>N3</b>	<p><del>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-);</del></p> <p><del>or metastasis in any node(s) with clinically overt ENE(+)</del></p>
<b>N3a</b>	<del>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)</del>
<b>N3b</b>	<del>Metastasis in any node(s) with clinically overt ENE(+)</del>

### Definition of Regional Lymph Node (N) Pathological N (pN) (紅字増修處)

N Category	N Criteria
<b>NX</b>	Regional lymph nodes cannot be assessed
<b>N0</b>	No <b>tumor involvement</b> of regional lymph node(s) <del>metastasis</del>
<b>N1</b>	<b>Tumor involvement</b> of 1-3 lymph node(s), without <b>definitive pathological extranodal extension</b> <del>Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(−)</del>
<b>N2</b>	<b>Tumor involvement</b> of > 3 lymph nodes <b>OR</b> <b>Tumor involvement</b> of any lymph node(s), with <b>definitive pathological extranodal extension</b> <del>Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(−) ;</del> <del>or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) ;</del> <del>or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−) ;</del> <del>or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)</del>
<b>N2a</b>	<del>Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+) ;</del> <del>or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)</del>
<b>N2b</b>	<del>Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension, and ENE(−)</del>
<b>N2e</b>	<del>Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(−)</del>
<b>N3</b>	<del>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−) ;</del> <del>or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+) ;</del> <del>or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+) ;</del> <del>or a single contralateral node of any size and ENE(+)</del>
<b>N3a</b>	<del>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)</del>
<b>N3b</b>	<del>Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+) ;</del> <del>or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+) ;</del> <del>or a single contralateral node of any size and ENE(+)</del>

### Definition of Distant Metastasis (M) (紅字増修處)

M Category	M Criteria
<b>cM0</b>	No distant metastasis
<b>cM1</b>	Distant metastasis
<b>pM1</b>	<b>Microscopic confirmation</b> of distant metastasis

### AJCC Prognostic Stage Groups (紅字增修處)

When T is...	And N is...	And M is...	Then the stage group is...
Tis	N0	M0	0
T1	N0	M0	I
T2	N0	M0	II
<del>T0</del> T1-T2 <del>T3</del>	N1	M0	III A
T3-T4	N0	M0	III A
<del>T4a</del>	<del>N0, N1</del>	<del>M0</del>	<del>IV A</del>
<del>T0</del> T1-T2 <del>T3</del> <del>T4a</del>	N2	M0	IV A III B
T3-T4	N1-N2	M0	IIIB
<del>Any T</del>	<del>N3</del>	<del>M0</del>	<del>IV B</del>
<del>T4b</del>	<del>Any N</del>	<del>M0</del>	<del>IV B</del>
Any T	Any N	M1	IV C

### References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>

[https://www.amazon.com/gp/product/B0G2TCQQBM?ref\\_=dbs\\_m\\_mng\\_rwt\\_calw\\_tkin\\_16&storeType=ebooks&qid=1763560154&sr=8-13](https://www.amazon.com/gp/product/B0G2TCQQBM?ref_=dbs_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13)